Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Bavaria
-
Munich, Bavaria, Germany
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Moderate to severe glabellar frown lines
Exclusion Criteria:
- Diagnosis of myasthenia gravis or Eaton Lambert syndrome
- Aesthetic treatment with botulinum toxin within 6 months or planned treatment with botulinum toxin for any reason during the study
- Prior filler treatments, surgeries, insertion procedures in/to the glabellar region
- Facial cosmetic procedures in the glabellar area within 6 months
- Bleeding disorders or use of anticoagulants within 10 days
- History of facial nerve palsy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Vistabel®
botulinum toxin type A (Vistabel®)
|
20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
Other Names:
30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
Other Names:
|
|
Active Comparator: Bocouture®
botulinum toxin type A (Bocouture®)
|
20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
Other Names:
30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Subjects With a Treatment Response at Day 28 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the Facial Wrinkle Scale (FWS)
Time Frame: Day 28
|
Number of subjects with a treatment response at Day 28 based on the injector's assessment of the severity of glabellar lines at maximum contraction using the FWS.
The FWS measures wrinkles on a scale from 0=none (best) to 3=severe (worst).
Treatment response was defined as a 1 point or greater reduction from Day 0 in the FWS score at maximum contraction.
|
Day 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Subjects With a Treatment Response at Day 84 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS
Time Frame: Day 84
|
Number of subjects with a treatment response at Day 84 based on the injector's assessment of the severity of glabellar lines at maximum contraction using the FWS.
The FWS measures wrinkles on a scale from 0=none (best) to 3=severe (worst).
Treatment response was defined as a 1 point or greater reduction from Day 0 in the FWS score at maximum contraction.
|
Day 84
|
|
Number of Subjects With a Treatment Response at Day 98 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS
Time Frame: Day 98
|
Number of subjects with a treatment response at Day 98 based on the injector's assessment of the severity of glabellar lines at maximum contraction using the FWS.
The FWS measures wrinkles on a scale from 0=none (best) to 3=severe (worst).
Treatment response was defined as a 1 point or greater reduction from Day 0 in the FWS score at maximum contraction.
|
Day 98
|
|
Number of Subjects With a Treatment Response at Day 112 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS
Time Frame: Day 112
|
Number of subjects with a treatment response at Day 112 based on the injector's assessment of the severity of glabellar lines at maximum contraction using the FWS.
The FWS measures wrinkles on a scale from 0=none (best) to 3=severe (worst).
Treatment response was defined as a 1 point or greater reduction from Day 0 in the FWS score at maximum contraction.
|
Day 112
|
|
Number of Subjects With a Treatment Response at Day 28 Based on the Subject's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS
Time Frame: Day 28
|
Number of subjects with a treatment response at Day 28 based on the subject's assessment of the severity of glabellar lines at maximum contraction using the FWS.
The FWS measures wrinkles on a scale from 0=none (best) to 3=severe (worst).
Treatment response was defined as a 1 point or greater reduction from Day 0 in the FWS score at maximum contraction.
|
Day 28
|
|
Number of Subjects With a Treatment Response at Day 84 Based on the Subject's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS
Time Frame: Day 84
|
Number of subjects with a treatment response at Day 84 based on the subject's assessment of the severity of glabellar lines at maximum contraction using the FWS.
The FWS measures wrinkles on a scale from 0=none (best) to 3=severe (worst).
Treatment response was defined as a 1 point or greater reduction from Day 0 in the FWS score at maximum contraction.
|
Day 84
|
|
Number of Subjects With a Treatment Response at Day 98 Based on the Subject's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS
Time Frame: Day 98
|
Number of subjects with a treatment response at Day 98 based on the subject's assessment of the severity of glabellar lines at maximum contraction using the FWS.
The FWS measures wrinkles on a scale from 0=none (best) to 3=severe (worst).
Treatment response was defined as a 1 point or greater reduction from Day 0 in the FWS score at maximum contraction.
|
Day 98
|
|
Number of Subjects With a Treatment Response at Day 112 Based on the Subject's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the FWS
Time Frame: Day 112
|
Number of subjects with a treatment response at Day 112 based on the subject's assessment of the severity of glabellar lines at maximum contraction using the FWS.
The FWS measures wrinkles on a scale from 0=none (best) to 3=severe (worst).
Treatment response was defined as a 1 point or greater reduction from Day 0 in the FWS score at maximum contraction.
|
Day 112
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MAF/AGN/Facial/011
- 2010-021401-20 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.